A PHASE 1, RANDOMIZED, DOUBLE-BLIND, VEHICLE AND ACTIVE COMPARATOR-CONTROLLED, PSORIASIS PLAQUE TEST STUDY TO ASSESS SAFETY, TOLERABILITY, AND PSORIATIC SKIN INFILTRATE THICKNESS FOLLOWING REPEATED, TOPICAL DOSES OF PF-06763809 SOLUTION IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS

The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers. Each subjects will receive three different topical doses of PF 06763809, PF 06763809 vehicle, and two active comparators. These will be applied to six different treatment fields for 18 days. The total duration of participation in the study will be approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval from Screening to the Follow up phone call visit.

开始日期2018-04-24

申办/合作机构

Pfizer Inc.

NCT01007591

/ Completed临床3期

Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas

An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and on the intertriginous areas

开始日期2009-10-01

申办/合作机构

Leo Pharma, Inc.

NCT00640822

/ Completed临床3期

A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas

There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares

开始日期2008-02-01

申办/合作机构

Leo Pharma, Inc.

100 项与卡泊三醇/氢化可的松相关的临床结果

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的转化医学

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的专利（医药）

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常性银屑病	临床3期	法国	Leo Pharma, Inc.	2009-10-01
银屑病	临床3期	欧盟	LEO Pharma A/S	-
银屑病	临床3期	加拿大	LEO Pharma A/S	-
银屑病	临床3期	法国	LEO Pharma A/S	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01007591 (CTgov)	临床3期	寻常性银屑病	40	LEO 80190 (LEO 80190 Ointment)	鬱繭艱鬱構觸簾衊襯襯(網餘餘簾膚築選選遞齋) = 廠廠蓋簾艱繭襯顧醖醖遞醖鑰鬱糧衊齋獵顧壓 (鬱窪選糧壓顧簾積膚淵, 壓獵衊蓋鬱顧艱壓製淵 ~ 鹽鹹醖齋觸壓遞構醖淵) 更多	-	2019-01-15
				Hydrocortisone (Hydrocortisone 10 mg/g Ointment)	鬱繭艱鬱構觸簾衊襯襯(網餘餘簾膚築選選遞齋) = 鹽窪簾鹽鹽醖壓網憲遞遞醖鑰鬱糧衊齋獵顧壓 (鬱窪選糧壓顧簾積膚淵, 餘鬱繭齋範艱顧襯夢觸 ~ 製壓鏇壓簾蓋製範選夢) 更多
NCT00640822 (CTgov)	临床3期	寻常性银屑病	782	Calcipotriol plus hydrocortisone ointment (Calcipotriol Plus Hydrocortisone Ointment)	襯鹽艱繭廠構蓋醖衊選(淵淵醖糧構簾餘鑰範醖) = 窪艱鑰遞構繭憲衊鹽網憲艱遞選顧鬱廠構顧壓 (網鏇網壓鏇願衊構鹹鬱, 簾鬱糧遞淵繭願鏇鏇窪 ~ 鏇憲簾艱齋廠糧鑰繭淵) 更多	-	2010-12-21
				Calcipotriol plus hydrocortisone ointment vehicle (Calcipotriol Plus Hydrocortisone Ointment Vehicle)	襯鹽艱繭廠構蓋醖衊選(淵淵醖糧構簾餘鑰範醖) = 襯衊壓製顧網積鹹蓋憲憲艱遞選顧鬱廠構顧壓 (網鏇網壓鏇願衊構鹹鬱, 選醖夢鹽艱淵醖願壓觸 ~ 醖鏇鬱壓鬱艱淵淵選鏇) 更多